Connect with us

Business

Emyria (ASX:EMD) share price falling on news of MDMA therapy trial

Published

on

Shares in Emyria Ltd (ASX: EMD) are falling today after the company shared news of a psychedelic therapy program targeting post traumatic stress disorder (PTSD). At its intraday low, the Emyria share price has fallen by 5%.

At the time of writing, it has slightly recovered. Currently, the Emyria share price is down 3.85% – trading for 25 cents.

Let’s take a closer look at the drug development and clinical services company’s news.

Emyria’s MDMA-assisted therapy trial

Emyria – formerly known as Emerald Clinics Limited – is set to sponsor a clinical trial targeting treatment resistant PTSD with MDMA-assisted therapy.

The trial has been developed in partnership with Mind Medicine Australia, a charity working to help end…



Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Sanjeev Gupta’s GFG Alliance looks to sell-off solar farm and battery project – ABC News
Rio Tinto defends not stripping bonuses from executives who left amid Juukan Gorge outcry – The Guardian